WOBURN, Mass., and RAMAT GAN, Israel, Nov. 13 /PRNewswire/ -- Predix Pharmaceuticals Inc., a G-Protein Coupled Receptor (GPCR) and ion channel (IC) focused discovery and early development company, has announced a partnership with RRD International, LLC to bring Predix's first compound into the clinic. Predix Pharmaceuticals Holdings, Inc. expects to file an IND to initiate a Phase I study for its proprietary serotonin 1A (5-HT1A) receptor agonist in early 2004.
The collaboration should allow the initiation of human studies of Predix's anti-anxiety compound in the first half of next year. The proposed indications for PRX-00023 are for the treatment of general anxiety disorder and other neuropsychiatric conditions. PRX-00023 is a full agonist targeted against the GPCR 5-HT1A receptor. The 5-HT1A program was initiated in early 2002 and led to the discovery and optimization of novel early development candidates in less than 18 months by using Predix's proprietary integrated computational -- medicinal chemistry platform.
"We believe PRX-00023 represents the first GPCR drug candidate discovered and optimized with in silico 3D GPCR models," said Dr. Michael Kauffman, President and CEO of Predix. Predix utilizes its proprietary PREDICT(TM) algorithm for the in silico generation of 3D GPCR models, then combines this with its suite of in silico screening and scoring algorithms. Lead molecules then undergo optimization using Predix's unique ICELER-3D(TM) algorithms. Kauffman added, "Moving a drug from in silico discovery, through optimization into clinical studies in less than two years represents a major milestone for the company and a validation of our unique technology platform."
RRD is assisting Predix in identifying the most appropriate regulatory and clinical strategy to expedite the development of PRX-00023. RRD is also responsible for preparing and filing the Investigational New Drug (IND) application and for conducting the first-in-man Phase 1 trial for the drug candidate. Dr. Chuck Finn, Chief Development Officer of RRD International, commented "We are excited about working closely with the team at Predix to ensure that its compounds that are moving rapidly out of discovery research maintain this momentum through the clinical development stages.
Predix is the developer of a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking is novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.
In addition to the 5-HT1A program, Predix is using its proprietary in silico GPCR models and computational platform for optimizing antagonists of serotonin 5-HT2B for pulmonary hypertension and pulmonary fibrosis, neurokinin-1 (NK1) for bladder incontinence and ulcerative colitis, and 5-HT4 for Alzheimer's Disease and other disorders. Additional programs are in early discovery, including the creation of in silico ion channel structural and functional models for anti-arrhythmic drug development.
Predix was incorporated in December, 2000, and is headquartered in Massachusetts, with its computational program in Ramat Gan, Israel. RRD International is located in Rockville, MD.
For More Information:
(781) 376-0821 Ext. 1010
Predix Pharmaceuticals Inc.